Lisa Rojkjaer - 17 Mar 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role: EVP, Chief Medical Officer
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol: RIGL
Transactions as of: 17 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 19 Mar 2025, 20:56:18 UTC
Previous filing: 31 Jan 2025
Next filing: 17 Sep 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RIGL	Employee Stock Option (right to buy)	Award	$0	+9,375		$0.000000	9,375	17 Mar 2025	Common Stock	9,375	$14.90	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met.
F2	The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met.

Content

The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met.

The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met.